Menenjiomlarda miRNA’lar Biyobelirteç Olarak Kullanılabilir mi?

Yıl 2022, Cilt: 17 Sayı: 3, 223 - 227, 02.11.2022

Hasan Dağlı , Özlem Gülbahar

https://doi.org/10.17517/ksutfd.1004412

Öz

Özet

Primer beyin tümörleri glial veya non-glial ve benign veya malign olarak sınıflandırılır. Menenjiomlar en yaygın görülen benign intrakranial tümörlerdir. Meningiom ismi ‘Meninks’ denilen beyin zarının tümörü anlamına gelse de aslında örümcek ağı şeklindeki ‘araknoid’ zarından (araknoid şapka hücrelerden) kaynaklandığı gösterilmiştir. Meningiomların büyük çoğunluğu iyi huylu, iyi sınırlı, yavaş büyüyen ve cerrahi ile tedavi edilebilir tümörlerdir. Menenjiom hastalarında prognozu en çok etkileyen rezeksiyonun derecesi ile histolojik derecedir. Dünya Sağlık Örgütü (DSÖ) sınıflamasına göre menenjiomların büyük çoğunluğu grade I (tipik/benign), %10’dan az bir kısmı grade II (atipik/intermediate) ve III (anaplastic/malign) tümörlerdir. Menenjiom tümörleri doku biyopsisi alınarak patolojik inceleme ile değerlendirilmektedir. Henüz tanısal ve prognostik amaçlı kullanılabilecek, non-invaziv olarak elde edilen kan örneklerinde çalışılabilecek bir biyobelirteç bulunmamaktadır. Girişimsel bir tanı yöntemi olan biyopsinin riskli olabilmesi ve değerlendirmenin subjektif olması gibi sebeplerle serum gibi non-invaziv örneklerde bakılabilecek biyobelirteçlere ihtiyaç vardır. MikroRNA’lar (miRNA) gen ekspresyonunu post-transkripsiyonel seviyede düzenleyen, 18-22 nükleotit uzunluğunda, endojen, protein kodlamayan RNA molekülleridir. Son yıllarda, miRNA’ların tümörler dâhil çeşitli patolojik durumlar için potansiyel biyobelirteç olmaları konusunda giderek artan araştirmalar yapılmaktadır. miRNA’lar belirli şartlar altında onkogen veya tümör supresor olarak fonksiyon görebilmektedirler. Proliferasyondan invazyona, metastazdan anjiogeneze kadar tümör oluşumu ve gelişimine katkıda bulunan birçok hücresel süreçte rol oynadıklarına dair kanıtlar vardır. Bu derlemede, bu moleküllerin menenjiyom teşhisi ve prognozundaki roller ve potansiyel terapötik etkilerini ele almayı amaçladık.

Anahtar Kelimeler

Menenjiom,, miRNA,, Biyobelirteç,, miR-145,, miR-34a-3p

Can miRNAs be Used As a Biomarkers in Meningioma’s?

Öz

Abstract

Primary brain tumors are classified as glial or non-glial and benign or malignant. Menenjiomas are common benign intracranial tumors. Although the name meningioma refers to a tumor of the lining of the brain called the ‘Meninx’, it has actually been shown to originate from the spider web-shaped ‘arachnoid’ membrane (arachnoid cover cells). The vast majority of meningiomas are benign, well circumscribed, slow growing and surgically treatable tumors. The degree of resection and histological degree are the most influential factors in the prognosis of meningioma patients. According to the World Health Organization (WHO) classification, the vast majority of menenjiomas are grade 1 (typical/benign), less than 10% grade II (atypical/moderate) and III (anaplastic/malignant) tumors. Menenjioma tumors are pathologically evaluated by taking tissue biopsy. There is no biomarker that can be used for diagnostic and prognostic purposes in blood samples obtained non-invasively. Biomarkers that can be evaluated in non-invasive samples such as serum are needed because biopsy, which is an interventional diagnostic method, can be risky and evaluation is subjective. MicroRNAs are 18-22 nucleotide-long, endogenous, non-protein-coding RNA molecules that negatively regulate gene expression at the post-transcriptional level. In recent years, there has been increasing research on miRNAs as potential biomarkers for various pathological conditions, including tumors. miRNAs can function as oncogenes or tumor suppressors under certain conditions. There is evidence that they play a role in many cellular processes that contribute to tumor formation and development, from proliferation to invasion, from metastasis to angiogenesis. In this review, we aimed to discuss the roles of these molecules in the diagnosis and prognosis of menenjioma, and their potential therapeutic effects.

Anahtar Kelimeler

Biomarker, Meningioma, miRNA, miR-145, miR-34a-3p

Kaynakça

• Gyawali S, Sharma P, Mahapatra A. Meningioma and psychiatric symptoms: an individual patient data analysis. Asian journal of psychiatry. 2019;42:94-103.
• TURNOG- Türk Nöroşirürji Derneği Nöroonkolojik Cerrahi Öğretim ve Eğitim Grubu https://www.turnog.com/turnogDATA/ userfiles/file/Meningiomlar.pdf (21.10.2021).
• Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncology. 2018;14(21):2161-2177.
• Katar S, Baran O, Evran S, Cevik S, Akkaya E, Baran G et al. Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA- 29b in meningioma. Clinical neurology and neurosurgery. 2017;156:66-70.
• Söylemezoğlu F. Meningiom sınıflaması ve histopatolojik özellikleri. Türk Nöroşirürji Dergisi. 2011;21:84-90.
• Murnyák B, Bognár L, Klekner Á, Hortobágyi T. Epigenetics of meningiomas. BioMed research international. 2015;2015:532451.
• Galani V, Lampri E, Varouktsi A, Alexiou G, Mitselou A, Kyritsis AP. Genetic and epigenetic alterations in meningiomas. Clinical neurology and neurosurgery. 2017;158:119-125.
• Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: A review. Journal of neuro-oncology. 1996;29(3):197-205.
• Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen–progestin therapy. New England Journal of Medicine. 2007;357(23):2411-2412.
• Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;110(3):471- 476.
• Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population‐based cohort study. British journal of clinical pharmacology. 2011;72(6):965-968.
• Nordenskjöld AC, Bujila R, Aspelin P, Flodmark O, Kaijser M. Risk of Meningioma after CT of the Head. Radiology. 2017;285(2):568-575.
• Carlberg M, Söderqvist F, Mild KH, Hardell L. Meningioma patients diagnosed 2007–2009 and the association with use of mobile and cordless phones: A case–control study. Environmental health. 2013;12(1):1-10.
• Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Current neurology and neuroscience reports. 2007;7(3):208-214.
• Yuniarti H, Subagio HW, Puruhita N, Murbawani EA, Nugrohowati AK, Priambada D et al. Body Mass Index and Waist Hip Ratio as a Risk Factor for Meningioma Incidence. Current Nutrition & Food Science. 2021;17(7):782-788.
• Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. Journal of neuro-oncology. 2010;99(3):307-314.
• Çelik AO, Umul A, Demirtaş H. Radiological Appearence of Unique Cystic Degeneration in Secretory Meningioma. Causa- Pedia 2015;4:1273.
• Wang L, Chen S, Liu Y, Zhang H, Ren N, Ma R et al. The biological and diagnostic roles of MicroRNAs in meningiomas. Rev Neurosci. 2020 Oct 25;31(7):771-778
• Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556-566.
• Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Molecular aspects of medicine. 2014;39:82-101.
• Ergun S, Tayeb TS, Arslan A, Temiz E, Arman K, Safdar M et al. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. Gene. 2015;555(2):377-381.
• Bukhari SI, Truesdell SS, Vasudevan S. Analysis of MicroRNA-mediated translation activation of in vitro transcribed reporters in quiescent cells. Methods Mol Biol. 2018;1686:251-264.
• Reddy KB. MicroRNA (miRNA) in cancer. Cancer cell international. 2015;15(1):1-6.
• Tie Y, Liu B, Fu H, Zheng X. Circulating miRNA and cancer diagnosis. Sci China C Life Sci. 2009 Dec;52(12):1117-1122
• Reddy KB. MicroRNA (miRNA) in cancer. Cancer cell international. 2015;15(1):38.
• Ergun S, Arman K, Temiz E, Bozgeyik I, Yumrutaş Ö, Safdar M et al. Expression patterns of miR-221 and its target Caspase- 3 in different cancer cell lines. Molecular biology reports. 2014;41(9):5877-5881.
• Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/β-catenin signaling pathway. Molecular and cellular biology.
• Redova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future oncology. 2013;9(3):387-402.
• Pardo O. Meningioma dissemination and growth: a role for microRNAs. Oncogene. 2015;34(14):1743-1744.
• Zhi F, Shao N, Li B, Xue L, Deng D, Xu Y et al. A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Scientific reports. 2016;6:32067.
• Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. Corrigendum: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011 Apr;13(4):423-433.
• Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-1414.
• Wang M, Deng X, Ying Q, Jin T, Li M, Liang C. MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. Biochemical and biophysical research communications. 2015;460(2):354-361.
• Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene. 2013;32(39):4712- 4720.
• Senol O, Schaaij-Visser T, Erkan E, Dorfer C, Lewandrowski G, Pham T et al. miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo. Oncogene. 2015;34(14):1790-1798.
• Mitha R, Shamim MS. Significance of micro-RNA expression in patients with meningioma. JPMA The Journal of the Pakistan Medical Association. 2020;70(7):1287.
• Ludwig N, Kim Y-J, Mueller SC, Backes C, Werner TV, Galata V et al. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs. Neuro-oncology. 2015;17(9):1250-1260.
• Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist. 2010;15(7):673.